Novavax Pushes Profitability Target to 2029
Novavax pushed its profitability target to 2029. Its shares dipped.
Related stories
BRIEF-Ramsay Sante Q1 EBITDA EUR 120.7 Million
BRIEF-Ramsay Sante Q1 EBITDA EUR 120.7 Million Nov 05 (Reuters) - Ramsay Sante Q1 revenue EUR 1,232.
L impact | EARNINGS | Nov 05, 2026, 04:38 PM UTC
PUNTO 3-Novavax posticipa l'obiettivo di redditività al 2029, azioni calano
PUNTO 3-Novavax posticipa l'obiettivo di redditività al 2029, azioni calano Novavax prevedeva di rag
L impact | EQUITY | Nov 05, 2026, 04:33 PM UTC
ACTUALIZA 3-Novavax retrasa su objetivo de rentabilidad hasta 2029; las acciones caen
ACTUALIZA 3-Novavax retrasa su objetivo de rentabilidad hasta 2029; las acciones caen Novavax espera
L impact | EQUITY | Nov 05, 2026, 04:33 PM UTC
LEAD 3-Novavax repousse son objectif de rentabilité à 2029, le titre recule
LEAD 3-Novavax repousse son objectif de rentabilité à 2029, le titre recule Novavax prévoyait d'atte
L impact | EQUITY | Nov 05, 2026, 04:33 PM UTC
Formycon Revises 2026 Adjusted EBITDA Guidance After Impairments
Formycon reported non-cash impairments of €39 million for FYB201 and €82 million for FYB202, citing increased competition and price pressure. It lowered adjusted EBITDA guidance to
M impact | EARNINGS | Nov 05, 2026, 04:33 PM UTC
Comer Industries Reports 48.2% Revenue Growth, Reaffirms Guidance
Revenue reached €979.9 million in the first nine months of 2026, including €220.6 million from Comtesco; like-for-like growth was 14.9% and EBITDA was €144.9 million.
M impact | EARNINGS | Nov 05, 2026, 04:33 PM UTC